Xeris In Recorlev-Fuelled Growth: Why I Choose To Buy

Xeris Biopharma Holdings (NASDAQ: XERS ) stock price has been on a bull run, especially for the past month (rising almost over 45%), mainly driven by a stellar set of Q2 2025 results, which saw revenue rising to anGamu Dave Innocent Pasi is a seasoned financial professional and writer, bringing a wealth of experience from his prior roles as a financial analyst and in investment research. With a strong background in analyzing financial statements, capital markets, and the macro-economy, Gamu has a proven tra ...